

2025

# INTERNATIONAL SOCIETY FOR VACCINES

International  
Society for  
VACCINES

## ANNUAL CONGRESS ORAL PROGRAMME

Tuesday 28 October 2025



08:00 - 10:00

### REGISTRATION

(Magnifica 4 & 5 Foyer – First Floor)

09:00 - 10:00

### WELCOME COFFEE Sponsored by GPN Vaccines

(Magnifica 1, 2, 3 Foyer – Ground Floor)

10:00 - 10:10

### OPENING SESSION

(Magnifica 4 & 5 – First Floor)

### WELCOME BY ISV PRESIDENT

Linda Klavinskis, King's College London, UK

### CO-CHAIR REMARKS:

Ed Rybicki, University of Cape Town, South Africa

Michael Schotsaert, Icahn School of Medicine at Mount Sinai, USA

Michelle Groome, University of the Witwatersrand, South Africa

10:10 - 10:40

### STANLEY PLOTKIN LECTURE:

(Magnifica 4 & 5 – First Floor)

### SESSION CHAIR: Linda Klavinskis, King's College London, UK

The Quest for a Safe and Effective HIV Vaccine:

An Odyssey of Scientific Innovation and Perseverance

Linda-Gail Bekker, Desmond Tutu HIV Centre, University of Cape Town, South Africa

10:40 - 12:00

### PLENARY SESSION 1:


#### Structure Based Vaccine Design

(Magnifica 4 & 5 – First Floor)

#### Session Chairs:

Michael Schotsaert, Icahn School of Medicine at Mount Sinai, USA

Lakshmi Krishnan, Life Sciences National Research Council Canada, Canada



10:40 - 11:05

AI-based engineering of stabilized glycoproteins to improve vaccine efficacy and manufacturability

Hans Langedijk, ForgeBio, Netherlands





11:05 - 11:30

Structure-Based Engineering of a *Borrelia burgdorferi* Vaccine Antigen Enhances Stability and Immunogenicity for Lyme Disease Prevention

Kalvis Brangulis, Riga Stradins University, Latvia

11:30 - 11:45

Harnessing Chaperone in Structure-based Vaccine Design: RNA-based Regulated Assembly of VLPs and NPS

Baik-Lin Seong, Yonsei University, South Korea

11:45 - 12:00

Structure-based vaccine design of viral hemagglutinin to induce broadly neutralizing responses against influenza A virus

Nicholas Morano, Columbia University, USA

12:00 - 13:30

**LUNCH** Sponsored by Dynavax  
(Cultivar Restaurant Ground Floor)  
(Additional Seating Bridge 1 & 2 – First Floor)

12:30 - 13:30

### Canadian NRC Workshop on Specific New Technology

(Omega – Ground Floor)

**SESSION CHAIR:** Lakshmi Krishnan, Vice President Life Sciences National Research Council Canada (NRC), Canada

Canada's Health Emergency Readiness Agency and plans for pandemic resilience  
Kasondra White, Director General, HERC/ISED, Canada

NRC's VERO Cell technology as a platform for low-cost production of viral vaccines  
Chun Fang Shen, Principal Research Officer, National Research Council Canada, Canada

Plant-made virus-like particle vaccines: A valuable platform both between and during pandemics  
Brian Ward, Professor, McGill University and Chief Medical Officer, Aramis Biotechnologies, Canada

Glycovax development model: a successful combination of commercial vaccine component production and proprietary innovative vaccines

Élodie Pastural, Director, Regulatory Affairs & Clinical Development, GlycoVax Pharma, Canada

Wrap-Up

Lakshmi Krishnan, Vice President Life Sciences National Research Council Canada (NRC), Canada


13:30-15:00

### PLENARY SESSION 2: Systems Approaches to Next Generation Vaccines

(Magnifica 4 & 5 – First Floor)

#### Session Chairs:

Ed Lavelle, Trinity College Dublin, Ireland  
Francesca Micoli, GSK, Italy



13:30 - 13:55

### Systems Vaccinology

Bali Pulendran, Stanford University, USA







13:55 - 14:20

**Systems Human Immunology: Immune Setpoint and Immune Health**

John Tsang, Yale School of Medicine, USA

14:20 - 14:35

**Breadth and Durability of RTS,S/AS01<sub>E</sub>-Induced Humoral Correlates of Protection in Controlled Human Malaria Infection and Field Efficacy Trials**

Lenny Moise, SeromYx Systems, USA

14:35 - 14:50

**Deciphering Immune Response Dynamics to the M72/AS01E Tuberculosis Vaccine Using Systems Transcriptomics**

Oluwaseun Taofeek, Crescent University, Nigeria

15:00 - 15:30

**COFFEE BREAK** Sponsored by Moderna  
(Magnifica 1,2,3 Foyer – Ground Floor)



15:30 - 17:35

CONCURRENT SESSION 1

Next Generation Tools and Technologies for Vaccine Development. **Session Chairs:** Branka Grubor-Bauk, University of Adelaide, Australia  
Lenny Moise, SeromYx Systems, USA

(Magnifica 4 & 5 – First Floor)

15:30 - 15:55

Advancing self-amplifying RNA as a vaccines platform - Robin Shattock, Imperial College London, UK

15:55 - 16:20

Targeting Antimicrobial Resistance (AMR) with Innovative Vaccines - Michael Kowarik, LimmaTech Biologics AG, Switzerland

16:20 - 16:35

Toward the Development of a Pan-Beta-Coronavirus Vaccine - Jeffrey Ulmer, TechImmune LLC, USA

16:35 - 16:50

Vaccines on Demand Are Within Reach: Validating Immunoinformatics-Driven Vaccine Design Through Preclinical and Clinical Applications - Anne De Groot, EpiVax Inc., USA

16:50 - 17:05

From Blood To Bench: Broad-Spectrum Bacterial Vaccine Targets Via Functional Antibody Discovery - Fadil Bidmos, Imperial College London, UK

17:05 - 17:20

Development of a Complement-Dependent mRNA Vaccine Candidate for Gonorrhoea for LMICs Enabled by AI-Powered Antigen Selection - Frances Lees, Afrigen Biologics, South Africa

CONCURRENT SESSION 2

Defending the Future: Vaccines, Emerging Threats, and One Health. **Session Chairs:** Alejandra Capozzo, Universidad Abierta Interamericana, Buenos Aires, Argentina  
Lars Frelin, Karolinska Institutet, Sweden

(Vista – First Floor)

Accelerating Vaccine Development for Future Outbreak: CEPI's 100 Days Mission - Jakob Cramer, Coalition for Epidemic Preparedness (CEPI), UK

Crimean-Congo Hemorrhagic Fever Virus (CCHFV): From the lab bench to clinical trial - Ali Mirazimi, Karolinska Institutet, Sweden

Safety, Tolerability and Immunogenicity of a First In Africa Vaccine Against Lassa Fever Virus, Synthetic DNA-Based Ino-4500, In a Phase 1b Clinical Trial In Healthy Ghanaian Adults - Mary Amoakoh-Coleman, Noguchi Memorial Institute for Medical Research / University of Ghana, Ghana

mRNA Vaccines Against Rift Valley Fever Virus and Marburg Virus - Alexander Bukreyev, University of Texas Medical Branch at Galveston, USA

Cross Reactivity Among Coronaviruses and The Development of Pan-Sarbecovirus and Pan-Betacoronavirus Vaccines Using a Protein Subunit Platform - Alyson Kelvin, University of Calgary Faculty of Veterinary Medicine, Canada

Targeted Ebola Vaccination Among Survivor Networks in the Democratic Republic of the Congo: A Feasibility Campaign Beyond Ebola Outbreak Context - Trésor Zola Matuvanga, Université de Kinshasa, Congo-Kinshasa

CONCURRENT SESSION 3

"Bright Sparks" in Vaccinology PhD Student Session. **Session Chairs:** Ebony Gary, The Wistar Institute, USA  
Alec Freyn, Moderna, USA

(Omega – Ground Floor)

The Mexican High-Resolution HLA Database And Its Use To Select And Validate T-Cell Epitopes For Vaccines - Arturo Liñan-Torres, National Autonomous University of Mexico, Mexico (15:30-15:40)

Ionisable Lipids Synthesised from Biorenewable Waste as Delivery Vehicles and Adjuvants in mRNA Vaccines - Dylan Kairuz, University of the Witwatersrand, South Africa (15:40-15:50)

Development of Stable Plant-Based Nanoparticle-Encapsidated mRNA Vaccines - Natalie Nel, University of Cape Town, South Africa (15:50-16:00)

Immunogenicity of Self-Amplifying RNA Vaccines Against Hepatitis B Virus - Nazia Samudh, University of the Witwatersrand, South Africa (16:00-16:10)

Using Single Cell RNA Sequencing to Assess Immunological Responses in Quails Injected with Porcine Circovirus-Like Particles - Lekita Govindasamy, University of Cape Town, South Africa (16:10-16:20)

Low Vitamin B12 Levels and Anaemia Are Associated with Impaired Pneumococcal Vaccine Responses in Young Kenyan Children - Kelvin Mokaya Abuga, KEMRI-Wellcome Trust Research Programme (16:20-16:30)







17:20 - 17:35

A FIH Dose-Escalation Trial of the Safety and Pharmacokinetics of Anti-SARS-CoV-2 DNA-Encoded Monoclonal Antibodies (DMAb) Formulated for Delivery by CELLECTRA in Healthy Adults - David Weiner, Wistar Institute, USA

Evaluation of the Safety and Efficacy of a Crimean-Congo Hemorrhagic Fever Vaccine - A One Health Approach - Catherine Olal, University of Texas Medical Branch at Galveston, USA

Superior Protection and Prevention of Transmission Upon Influenza Infection By Adjuvanted Mucosal Vaccination in the Guinea Pig Influenza Model - Vivian Yan, Icahn School of Medicine at Mount Sinai, USA, **(16:30-16:40)**

Enhanced Mucosal SARS-CoV-2 Immunity After Heterologous Intramuscular mRNA Prime/Intranasal Protein Boost Vaccination with a Combination Adjuvant - Gabriel Laghali, Icahn School of Medicine at Mount Sinai, USA **(16:40-16:50)**

Seroprevalence, Associated Risk Factors, and Molecular Detection of Brucella spp. in Cattle, Sheep, Goats and Humans in Mvomero District, Morogoro, Tanzania - Emmanuel Lita, Sokoine University of Agriculture, Tanzania **(16:50-17:00)**

Evaluation of Highly Conserved Burkholderia pseudomallei Proteins as pan-Burkholderia Vaccine Antigen Candidates - Alexander Badten, University of Texas Medical Branch, USA **(17:00-17:10)**

Gut Microbiota Serve as Biomarkers to Predict Antibody Response to the Domestic Herpes Zoster Live Attenuated Vaccine in China - Simin Li, The Jiangsu Provincial Center for Disease Control and Prevention, China **(17:10-17:20)**

Development of Crimean-Congo Haemorrhagic Fever Chadox2-Vectored Vaccines with First-In-Human, Phase 1 Clinical Trial Progression - Jack Saunders, University of Oxford, UK **(17:20-17:30)**





17:35-18:00

**TRAINEE CONGRESS TRAVEL AWARD PRESENTATIONS**

(Magnifica 1,2,3 - Ground Floor)

17:35-20:00

**WELCOME RECEPTION** Sponsored by VisMederi

(Magnifica 1,2,3 + Foyer - Ground Floor)

18:00-20:00

**POSTER SESSION 1**

(Magnifica 1,2,3 - Ground Floor)

**Wednesday 29 October 2025**

08:00 - 08:30

**WELCOME COFFEE** Sponsored by Mabtech

(Magnifica 1,2,3 Foyer - Ground Floor)

08:30 - 09:00

**MORNING SESSION****SESSION CHAIR:** Jeff Ulmer, TechImmune LLC, USA

(Magnifica 4 &amp; 5 – First Floor)

**KEYNOTE LECTURE:**

Nucleoside-modified mRNA-LNP therapeutics

Drew Weissman, University of Pennsylvania, USA

09:00 - 10:35


**PLENARY SESSION 3:**

(Magnifica 4 &amp; 5 – First Floor)

**Climate, Environment and Vaccination: Responding to a Changing World****Session Chairs:**

Ed Rybicki, University of Cape Town, South Africa

Sarah Gilbert, University of Oxford, UK



09:00 - 09:25

Using genomics to characterize and respond to climate amplified disease and epidemics

Tulio de Oliveira, Stellenbosch University, South Africa

09:25 - 09:50

**Dengue: global epidemiology and strategies for prevention and control**

Fernanda Boulos, Butantan Institute, Brazil

09:50 - 10:05

A Multi-Antigen DNA Vaccine Induces Mucosal Immune Protection From Valley Fever, A Respiratory Fungal Disease that is Spreading Due to Climate Change

Deborah Fuller, University of Washington, USA

10:05 - 10:20

A Phase III randomized controlled multi-centre trial evaluating the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria

Angela Gwakisa, Ifakara Health Institute (IHI), Tanzania

10:20 - 10:35

Tracking the Spread of Antimalarial Drug Resistance: Molecular Markers Analysis in Central and South-Eastern Senegal, 2019

Mamadou Yade, International Center for Research and Training on Applied Genomics and Health Surveillance (CIGASS), Mali

10:35 - 11:00

**COFFEE BREAK** Sponsored by Sanofi

(Magnifica 1,2,3 Foyer – Ground Floor)







11:00 - 12:35

CONCURRENT SESSION 4

Mpox And Other Vectored Vaccines.

Session Chairs:

Anna-Lise Williamson, University of Cape Town, South Africa  
Kai Dallmeier, KU Leuven, Belgium

(Magnifica 4 & 5 – First Floor)

11:00 - 11:25

The Emergence of Clade Ib, an accident waiting to happen - Laurens Liesenborghs, Institute for Tropical Medicine, Antwerp, Belgium

11:25 - 11:50

The Role of MVA-BN in Mpox Management: Current Data and Future Directions - Melvin Sanicas, Bavarian Nordic, Switzerland

11:50 - 12:05

Genetic Diversity and Population Structure of Mpox Virus In Africa: Identifying Key Targets for Vaccine Development - Abubakar Woziri, Ahmadu Bello University, Nigeria

12:05 - 12:20

Utilizing the VSV Vector Approach for Emerging Infections Disease Vaccine Development - Marija Zaric, IAVI, UK

12:20 - 12:35

A New Single-Virus MMR Vaccine: Measles-Based Vector Expressing Rubella and Mumps Antigens - Phanramphoei Frantz Institut Pasteur, France

CONCURRENT SESSION 5

Vaccines And Immunotherapeutics Against Mucosal Pathogens. Session Chairs:

Adam Cunningham, University of Birmingham, UK  
Denise Doolan, University of Queensland, Australia

(Vista – First Floor)

Shigella Vaccines – Advancing Innovation to Combat a Global Health Threat - Francesca Micoli, GSK, Italy

Humoral and mucosal immunity, and retention of attenuated phenotype: results of a phase 1 study of novel type 1 and 3 OPVs - Chris Gast, PATH, USA

A Potent Monoclonal Antibody Against Gonococcal Lipooligosaccharide with Enhanced Effector Function and Half-Life - Davinder Gill, StIRx Inc, USA

Swab And Spray: A Proposal for Future Precision Immunization Against Respiratory Infections Through Infection Risk Assessment and Nasal Vaccination - Ling Chen, Guangzhou Medical University, China

Engineered Design of Mucus Penetration Nanoparticles for Inhalable Vaccines - Bingbing Sun, Dalian University of Technology, China

CONCURRENT SESSION 6

“Bright Sparks” in Vaccinology ECR session.

Session Chairs:

Linda Klavinskis, King's College London, UK  
David Weiner, The Wistar Institute, USA

(Omega – Ground Floor)

Cytomegalovirus viral Fc gamma receptors as vaccine antigens to enhance anti-viral Fc-mediated effector antibody functions - Claire Otero Weill Cornell Medicine, USA (11:00-11:10)

Oral Immunization with Filoviral-Like Particles Elicits Ebola-Specific Humoral and Cellular Immune Responses and Confers Protection from Ebola Challenge In Mice - Juan Garcia-Bernalt Diego, Centro de investigación Hospital Universitario 12 de Octubre, Spain (11:10-11:20)

Intranasal Spike Protein with Mucosal Combination Adjuvant: Potential for Mucosal Booster Vaccination After Intramuscular mRNA Vaccine Against SARS-CoV-2 - Seokchan Park, Icahn School of Medicine at Mount Sinai, USA (11:20-11:30)

Age-Dependent Immune Profiling and Spatial Resolution of HIV-1 Subtype C Reservoirs in Human Tonsillar Tissues - Faiaz Shaik Abdool, Africa Health Research Institute, South Africa (11:30-11:40)

Empty Vector Plasmid DNA in Lipid Nanoparticles is a Potent Adjuvant for Recombinant Protein Vaccines - Nicholas Tursi, The Wistar Institute, USA (11:40-11:50)





M72/AS01E Vaccination Boosts Polyfunctional Effector Memory CD4+ T Cell Populations That May Serve as Immune Correlates of Protection - Sharon Khuzwayo, Cape Town HVTN Immunology, South Africa **(11:50-12:00)**

Durability and Functional Profile of T Cell Responses to SARS-CoV-2 After Multiple Vaccinations in People Living with HIV - Maxine Hoft, University of Cape Town, South Africa **(12:00-12:10)**

Development of a Genotype-Matched Newcastle Disease DNA Vaccine Candidate Adjuvanted with IL-28b for the Control of Targeted Velogenic Strains of Newcastle Disease Virus in Africa - Charlie Amoia, SACIDS Foundation for One Health, Tanzania **(12:10-12:20)**

Development of Plant-Made Ms-1797: A Low-Cost Monoclonal Antibody for Malaria Prevention - Christine Bulaon, Baiya Phytopharm Co., Ltd., Thailand **(12:20-12:30)**







12:35 - 14:00

**LUNCH** *Sponsored By Pfizer*  
(Cultivar Restaurant Ground Floor)  
(Additional Seating Bridge 1 & 2 – First Floor)

13:00 - 14:00

**ROUNDTABLE:**  
Building Sustainable mRNA Vaccine Capacity in LMICs  
(Omega - Ground Floor)

**ORGANIZERS:**  
Robin Shattock/Sarah Joseph, Imperial College London, UK  
Pierre Gsell, WHO, Switzerland

**DISCUSSION CHAIR:** Robin Shattock, Imperial College London, UK

**PARTICIPANTS:**  
Caryn Fenner, Afrigen, South Africa  
Ebrahim Mohammed, Biovac, South Africa  
Pierre Gsell, WHO, Switzerland  
Nicaise Ndembi, IVI, Rwanda  
Drew Weissman, University of Pennsylvania, USA  
Sina Mozaffari-Jovin, Max-Planck Institute, Germany

13:00 - 14:00

**PANEL DISCUSSION FOR ECR'S:**  
Vaccines we have not Considered Yet, Vaccines for Space Travel  
(Vista - First Floor)

**PANELISTS:**  
Nicole Steinmetz, University of California, USA  
Alejandra Capozzo, Universidad Abierta Interamericana, Buenos Aires, Argentina

14:00 - 15:30

**POSTER SESSION 2**  
(Magnifica 1,2,3 – Ground Floor)

14:30 - 15:30


**ISV ANNUAL GENERAL MEETING**  
(Omega - Ground Floor)

15:30 - 16:00

**COFFEE BREAK** *Sponsored By Bavarian Nordic*  
(Magnifica 1,2,3 Foyer – Ground Floor)

16:00 - 17:35

**PLENARY SESSION 4:** (Magnifica 4 & 5 – First Floor)  
**Maternal and Infant Vaccination in Preventing Disease**  
**Session Chairs:**  
Michelle Groome, University of the Witwatersrand, South Africa  
Neil Almond, MHRA (NIBSC), UK





16:00 - 16:25

Opportunities and challenges in prevention of respiratory syncytial virus in infants through maternal immunization

Shabir Madhi, University of the Witwatersrand, South Africa

16:25 - 16:50

New Horizon of RSV Lower Respiratory Disease in infants: Real-World Impact with a Monoclonal Antibody in all Infants

Danilo Casimiro, Vaccine R&D, Sanofi, USA

16:50 - 17:05

How Can We Unlock Inflationary CMV-Specific T Cell Immunity During Pregnancy in the Design of a Maternal Vaccine Against CMV

Brandon Paarwater, Stellenbosch University, South Africa

17:05 - 17:20

Embarking on a Path of Clinical Development of A Haemophilus Influenzae Type A Vaccine

Joanne Langley, Dalhousie University, Canada

17:20 - 17:35

Long-Term Immunogenicity of a Single Dose Compared with a Two-Dose Primary Series Followed by a Booster Dose Of 10- Or 13-Valent Pneumococcal Conjugate Vaccines In South African Children Up To 5 Years Of Age: An Open-Label, Randomised, Non-Inferiority Trial

Daniel Kapelus, University of Witwatersrand, South Africa

18:00

**PICK UP FOR GALA DINNER**

(Protea Hotel Front Entrance)

## Thursday 30 October 2025



08:00 - 08:30

**MORNING COFFEE** Sponsored by Inovio Pharmaceuticals, Inc  
(Magnifica 1,2,3 Foyer-Ground Floor)

08:30 - 09:00

**MORNING SESSION**

**SESSION CHAIR:** Margaret Liu, ProTherImmune & Karolinska Institutet, USA & Sweden

**KEYNOTE LECTURE:** Novel TB vaccines: is control of the global epidemic on the horizon?  
Willem Hanekom, Africa Health Research Institute, South Africa


09:00 - 10:35

**PLENARY SESSION 5:**  
**Progress in Therapeutic Cancer Vaccines**

(Magnifica 4 & 5 – First Floor)

**Session Chairs:**

David Weiner, The Wistar Institute, USA



09:00 - 09:25

RNA Vaccines for Pancreatic Cancer

Vinod Balachandran, Memorial Sloan Kettering Cancer Center, USA

09:25 - 09:50

NanoEngineering gone viral: plant virus-based immunotherapy

Nicole Steinmetz, University of California, USA







09:50 - 10:05

An mRNA Cancer Vaccine Encoding a DC-Targeting Peptide and Flagellin Induces Potent Antitumor Responses in a Murine Model

Joon Haeng Rhee, Chonnam National University, South Korea

10:05 - 10:20

Novel Nanokine-Tm Technologies to Control Regulatory Immunity for New Immunotherapy Treatments for Infectious Disease and Oncology

Ursula Gompels, Virothera Ltd, UK

10:20 - 10:35

Immunotherapy, INO-3107, is Well-Tolerated, Effective, and Elicits an Antigen-Specific T-cell Response in Adults with HPV-6 & 11 Recurrent Respiratory Papillomatosis

Jacqueline Shea, Inovio Pharmaceuticals, Inc., USA

10:35-10:55

**COFFEE BREAK** Sponsored By EuBiologics Co. Ltd.  
(Magnifica 1,2,3 Foyer – Ground Floor)





10:55 - 12:45

CONCURRENT SESSION 7

What's New in HIV Vaccine Development.

Session Chairs:

Shan Lu, Worcester HIV Vaccine (WHV) and UMASS Chan Medical School, USA  
Robin Shattock, Imperial College London, UK

(Magnifica 4 & 5 – First Floor)

10:55 - 11:20

Targeting HIV broadly neutralizing antibody precursors in humans with atomic precision - Rogier Sanders, University of Amsterdam, The Netherlands

11:20 - 11:45

Characterizing HIV breakthrough infections from large antibody-mediated prevention trials: Mechanisms of escape and implications for vaccine design - Carolyn Williamson, University of Cape Town, South Africa

11:45 - 12:00

Engineering Cytoplasmic Domains of Stabilized mRNA Env Immunogens Enhances Neutralizing Response - Edward Kreider, University of Pennsylvania School of Medicine, USA

12:00 - 12:15

Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After Shiv Challenge - Rosamund Chapman, University of Cape Town, South Africa

12:15 - 12:30

Concurrent Schistosoma Mansonii Infection Suppresses Induction Of HIV-1 Neutralizing Antibodies in a DNA/MVA/Gp140 Env Vaccine Regimen in Rhesus Macaques - Gerald Chege, South African Medical Research Council, South Africa

12:30 - 12:45

CONCURRENT SESSION 8

Unlocking Immunity: Mechanistic Insights Driving Next Gen Vaccine Design.

Session Chairs:

Michael Schotsaert, Icahn School of Medicine at Mount Sinai, USA  
Frédéric Tangy, Institute Pasteur, France

(Vista – First Floor)

Focusing on conserved immunogenic regions results in broad breadth of Betacoronavirus virus T cell recognition - Alba Griffoni, La Jolla Institute, USA

Interferons and inflammasomes as mediators of adjuvant induced immunity - Ed Lavelle, Trinity College Dublin, Ireland

CD4+ T Cell Responses After mRNA-1273 SARS-CoV-2 Vaccination in People Living with HIV are Associated with Risk of COVID-19 - Erica Andersen-Nissen, Cape Town HVTN Immunology Laboratory, South Africa

Tolerogenic mRNA-Lipid Nanoparticle Vaccines for Autoimmune Disease - Jilian Melamed, University of Pennsylvania, USA

Convergent and Clonotype-Enriched Mutations Drive Affinity Maturation of a Public Antibody - Vishal Rao, Icahn School of Medicine at Mount Sinai, USA

Harnessing The Potential of mRNA Vaccines Against Hepatitis C Virus - Branka Grubor-Bauk, University of Adelaide, Australia

CONCURRENT SESSION 9

Public Health Approaches in Vaccinology.

Session Chairs:

Davinder Gill, StIRx Inc, USA  
Tim Hirst, GPN Vaccines, Australia

(Omega – Ground Floor)

Can vaccines move cholera ahead of the epidemic curve - Lucille Blumberg, National Institute for Communicable Diseases, South Africa

Harnessing respiratory virus vaccines for public health impact - Cheryl Cohen, University of the Witwatersrand, South Africa

Neutralizing Antibody Titers Predict Protection from Virus Transmission in a Cohort of Household Members with Documented Exposure to SARS-CoV-2 - Luka Cicin-Sain, Helmholtz Centre for Infection Research, Germany

Factors Influencing Influenza Vaccine Uptake Among Adults in Johannesburg, South Africa: A Qualitative Study - Mulalo Mashamba, Vaccines and Infectious Diseases Analytics Research Unit, South Africa

Perception of Disease Severity Drives Willingness for Cholera Vaccine Uptake: Evidence From a Covid-19 Surveillance Cohort - Andrew Musyoki, Sefako Makgatho Health Sciences University, South Africa

Mpox Vaccination in Africa: One Year On - Lessons and Milestones From the Continental Response - Charles Ibeneme, Africa Centers for Disease Control and Prevention, Zambia







12:45 - 14:00

**LUNCH** Sponsored By Vaxxas  
(Cultivar Restaurant Ground Floor)  
(Additional Seating Bridge 1 & 2 – First Floor)

13:00 - 14:00

**VAXXAS WORKSHOP:**

Enabling At-Home Vaccination: Technologies For Self-Administration  
(Omega-Ground Floor)

**PRESENTER:** Alexandra Depelsenaire, Vaxxas Pty Ltd, Australia

**MODERATOR:** Manon Cox, NextWaveBio, USA

13:00 - 14:00

**CAREER DEVELOPMENT WORKSHOP**

(Vista-First Floor)

**CHAIR:** Michael Schotsaert, Icahn School of Medicine at Mount Sinai, USA

**PANELISTS:**

Jamie Pillaye, BactiVac Network, UK

Elloise du Toit, GARP-SA, South Africa

Maranyane Hapiloe, Afrigen, South Africa

Erica Andersen-Nissen, Cape Town HVTN Immunology Laboratory, South Africa

Alec Freyn, Moderna, USA

14:00 - 14:30

**AWARD CEREMONY**

(Magnifica 4 & 5 – First Floor)

14:30 - 14:55

**ISV PAPER OF THE YEAR:**

**CHAIR:** Linda Klavinskis, King's College London, UK

Development of a quadrivalent mRNA-lipid nanoparticle vaccine to elicit cross-reactive immune responses against diverse Orthopoxviruses

Alec Freyn, Moderna, USA

14:55 - 16:05


**PLENARY SESSION 6:**

(Magnifica 4 & 5 – First Floor)

**Cutting-Edge Innovations in Vaccine Manufacturing:****The Future of Scalable Production****Session Chairs:**

Manon Cox, NextWaveBio, USA

Danilo Casimiro, Vaccine R&D, Sanofi, USA



14:55 - 15:20

Advancing sustainable local vaccine manufacturing through end-to-end project support  
Nicaise Ndembu, DDG, IVI, Africa

15:20 - 15:45

Development of bacterial vaccines and strategic collaboration for regional vaccine manufacturing.

Sin-Hee Jun, EuBiologics Co.Ltd., South Korea





15:45 - 16:05

### CLOSING SESSION

2025 Conference Reflections

Ed Rybicki, University of Cape Town, South Africa  
(Magnifica 1,2,3 Foyer-Ground Floor)

### INTRODUCTION TO 2026 ISV CONGRESS (Antwerp, Belgium)

Michael Schotsaert, Icahn School of Medicine at Mount Sinai, USA

17:30 - 19:30

### NEXT GENERATION VACCINOLOGIST ECR NETWORKING

**SOCIAL EVENT** Sponsored By The Biovac Institute  
(Bridge 1 – First Floor)





# NOTES

[illegible]

# NOTES

This image shows a single sheet of white paper with horizontal blue or grey ruling lines. The lines are evenly spaced and run across the width of the page. There are approximately 20 lines visible. The paper has a slight shadow on the right side, suggesting it's resting on a surface.